Feasibility of a Technology-Based Intervention for Depression Referral Uptake in Cancer Survivors
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Jul 21, 2025
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help cancer survivors who are feeling depressed get connected to the care they need. Depression is common among people who have had cancer, but it can be hard to find the right treatment quickly. This study will test if sending text messages to patients is a good and easy way to guide them toward getting help for their depression.
People who might take part in this study are adults (over 18) who have been diagnosed with cancer, have an upcoming appointment at a cancer clinic, speak English, own a cellphone that can receive text messages, and show signs of depression based on a simple screening test. However, those who have trouble with memory or thinking, or who are already getting counseling for depression, will not be eligible. If you join the study, you can expect to receive text messages designed to help you take steps toward getting support for depression. This study is just starting and is not yet enrolling participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \> 18 years
- • diagnosis of cancer
- • upcoming appointment in an HCC or HCN oncology clinic within 14 days
- • English proficiency
- • ownership of a cellphone with SMS text capability.
- • elevated depressive symptoms at screening (as measured by \> 3 on the PHQ-2)
- Exclusion Criteria:
- • cognitive impairment as evaluated by attending physician
- • currently receiving counseling for depression
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Katherine Sterba, PhD
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported